Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Centerview's Tokat Sees Potential for Mega Pharma Deals in 2026
A more permissive regulatory environment and Big Pharma's need to replenish revenue pipelines could spur the first $20 billion-plus M&A drug deal in more than three years, according to Centerview Partners Co-President Eric Tokat. “If there…
Trump administration urged to take on China's 'Pharma Death Grip
The push comes as policymakers recognize the United States relies heavily on China for key pharmaceutical materials, particularly the raw components of many antibiotics, while producing a small share domestically, China specialist Gordon Chang…
EU-approved sterile pharma facility launched
The launch of Sri Lanka's first locally manufactured self-dialysis solution bags by Kelun Lifesciences has coincided with the World Kidney Day. The company said the new supply bags, designed for home-based self-dialysis treatment, would benefit…
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Zealand Pharma A/S (ZLDPF) Barclays 28th Annual Global Healthcare Conference March 11, 2026 2:00 PM EDT Adam Steensberg - President & CEO Yihan Li - Barclays Bank PLC, Research Division Barclays Bank PLC, Research Division Hey, good afternoon…
Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest
HERZLIYA, Israel and CALGARY, AB, March 11, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that it intends to complete an offering of a debenture of the Company (the…
Ascendis Pharma A/S $ASND Shares Bought by Atika Capital Management LLC
Atika Capital Management LLC grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,160 shares of the…
Polling Reveals a Profound Shift on Vaccines: We Can't Let Pharma Bury It
Due to widespread media and scientific censorship, accurate information challenging pharmaceutical interests is difficult to obtain. Polling offers a unique means to bypass this blockade Extensive polling shows 9% to 34% of COVID vaccine recipients…
Global And Indian Market Update: Energy Siege And Escalation Of Trade War
Oil And Blood in the Persian Gulf: The global energy market has entered War-Risk Overdrive. Despite the IEA's unprecedented release of 400 million barrels of emergency oil (172 million from the US alone), WTI Crude has surged past $94/bbl. Markets…
Obesity Drug Can't Be Advertised Anymore
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'…
Full Year 2025 Trading Update
Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for…
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q4 2025 Update
Duquesne Family Office's 13F portfolio value rose to ~$4.49B in Q4 2025, with 35 significant positions led by Natera, Insmed, Amazon.com, Teva Pharma, and Woodward. Major new stakes include Alcoa, Entegris, Lattice Semi, Bloom Energy, and Delta…
Harbor Health Care ETF Q4 2025 Commentary (MEDI)
During the fourth quarter, the Harbor Health Care ETF returned 10.43% (NAV), underperforming the Russell 3000 Growth Health Care Index, which returned 16.71%. The underperformance was primarily driven by stock selection and relative underexposure…
Markets Crash Nearly 2%: BSE Sensex tumbled 1,342 pts; NSE Sinks Below 24K
Indian stock markets witnessed a sharp decline as the Sensex and Nifty tumbled due to surging crude oil prices, continuous foreign fund outflows, and selling pressure in key banking stocks, reflecting investor concerns over global economic…
AptarGroup Isn't Ready For An Upgrade Just Yet (NYSE:ATR)
AptarGroup remains a soft 'Sell' as valuation is still high relative to peers despite solid operational performance. Revenue growth is robust across all segments, especially pharma and beauty, but margin pressures and mixed profitability persist.
Markets Open Lower Amid West Asia Tensions, Oil Spike
The benchmark indices came under pressure after reports that Iran's Navy Chief warned vessels sailing through the Strait of Hormuz would require Iran's approval or risk being targeted, raising concerns about disruptions in global oil supply. The…
Receive a Daily briefing on Pharma Industry News
Get Started